Biogen Inc

26.06.2026 г., 19:51 ч. UTC

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

25.06.2026 г., 22:36 ч. UTC

Biogen Inc's shares are higher in after-market trading, reflecting a notable upward trajectory since Thursday's close amid mixed broader market results.

24.06.2026 г., 20:04 ч. UTC

Biogen Inc shares are higher today, supported by a broader rally in the Biotechnology sector and increased interest noted on social media.

23.06.2026 г., 23:21 ч. UTC

Biogen Inc shares are higher in after-market trading, reaching a session high. No specific news was identified to explain the unusual price movement.

22.06.2026 г., 23:46 ч. UTC

Biogen Inc. shares traded lower in after-market hours following modest fluctuations since Monday's close, with the price dipping after a brief session high.

18.06.2026 г., 20:05 ч. UTC

Biogen Inc. plans to acquire RayThera Inc. for up to $1 billion, but shares are declining amid broader Biotechnology sector weakness.

17.06.2026 г., 23:06 ч. UTC

Biogen Inc announced a definitive agreement to acquire RayThera Inc. for up to $1 billion, enhancing its immunology pipeline. Shares are trading higher after the news.

16.06.2026 г., 19:46 ч. UTC

Biogen Inc. shares are lower amid an investigation announcement linked to the Phase 2 CELIA study's failure and failed negotiations over Skyclarys.

12.06.2026 г., 19:51 ч. UTC

Biogen Inc. shares are higher today, breaking a recent trend. Broader market sentiment is shaped by inflation concerns and optimism about upcoming IPOs.

11.06.2026 г., 19:51 ч. UTC

Biogen Inc is advancing as the biotechnology sector gains. Earlier in the session, shares pulled back from a high but resumed their upward trajectory.

10.06.2026 г., 19:36 ч. UTC

Biogen Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 2 CELIA study results. Shares are trading lower amid ongoing scrutiny.

9.06.2026 г., 23:16 ч. UTC

Biogen Inc. shares declined in after-market trading, moving lower since Tuesday's close. The asset remains above its 20-day moving average.

8.06.2026 г., 20:06 ч. UTC

Biogen Inc. shares are lower amid negative sentiment over its Phase 2 CELIA study results, despite a recent upgrade to a Buy rating.

5.06.2026 г., 19:16 ч. UTC

Biogen shares are gaining following FDA's Breakthrough Therapy Designation for salanersen in spinal muscular atrophy, despite pulling back from earlier session highs.

4.06.2026 г., 22:06 ч. UTC

Biogen Inc. received FDA Breakthrough Therapy Designation for salanersen, aimed at treating spinal muscular atrophy, with shares trading higher in after-market hours.

3.06.2026 г., 20:03 ч. UTC

Biogen Inc. announced fourteen abstracts accepted for presentation at upcoming nephrology congresses, contributing to higher trading shares amid positive market sentiment.

2.06.2026 г., 20:06 ч. UTC

Biogen Inc. shares declined during Tuesday's session, continuing a trend of lower closes, amid broader weakness in the biotechnology sector.

1.06.2026 г., 19:26 ч. UTC

Biogen shares are lower following positive Phase 3 trial results for dapirolizumab pegol, despite significant improvements in disease activity for lupus patients.

29.05.2026 г., 19:26 ч. UTC

Biogen Inc. shares are trading lower today, reversing a recent trend of higher daily closes since Thursday's close. No specific news was identified.

28.05.2026 г., 20:06 ч. UTC

Biogen Inc shares are lower, continuing a downward trend since Wednesday. No specific news was identified to explain today's movement.

27.05.2026 г., 20:06 ч. UTC

RBC Capital raised its price target on Biogen Inc to $227, supporting shares' overall gain during Wednesday's trading amid positive pipeline developments.

26.05.2026 г., 19:56 ч. UTC

Biogen Inc. shares are lower following concerns over the failure of its Parkinson's drug BIIB122 in a Phase 2b trial.

22.05.2026 г., 19:37 ч. UTC

Biogen shares are higher following the Phase 2b LUMA study results for BIIB122, which showed over 90% kinase inhibition despite not meeting primary endpoints.

21.05.2026 г., 23:02 ч. UTC

Biogen Inc. shares declined in after-market hours following the failure of its Parkinson's treatment, BIIB122, to meet key trial endpoints in the Phase 2b LUMA study.

20.05.2026 г., 23:51 ч. UTC

Biogen Inc. shares are trading lower in after-market hours, reflecting broader market declines amid weak sentiment and macroeconomic factors affecting various sectors.

19.05.2026 г., 23:36 ч. UTC

Biogen Inc shares are trading higher in after-market hours, showing a modest recovery from earlier losses amid broader market caution over inflationary pressures.

18.05.2026 г., 19:15 ч. UTC

Biogen shares are lower amid negative sentiment from its CELIA trial results, which failed to meet primary endpoints, and ongoing investigations into potential securities violations.

15.05.2026 г., 19:56 ч. UTC

Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals, enhancing its drug portfolio. Shares are trading higher amid positive analyst ratings and target price increases.

14.05.2026 г., 23:01 ч. UTC

Biogen shares rose in after-market hours following positive topline results from the Phase 2 CELIA study on diranersen for early Alzheimer's disease.